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ABSTRACT
 
The risk is uncertain, so patients should make an informed decision
 
 
Success in giving up smoking can be improved through social support, problem
solving or skills training, and various drugs. A combination of drugs and other treatments
is most effective.1 Drugs include nicotine replacement products, varenicline (Champix),
and bupropion (Zyban and generics). Varenicline and bupropion inhibit the craving to
smoke through unknown mechanisms. Both drugs influence the dopamine system, which
regulates cognition, mood, and behaviour.2 Both varenicline and bupropion have been
associated with “changes in behaviour, agitation, depressed mood, suicidal ideation,
and attempted and completed suicide” in patients who had no psychiatric history and
were not taking psychotropics.3 4 Nicotine replacement products have no such known
associations.3 In the linked study (doi:10.1136/bmj.b3805), Gunnell and colleagues
report the first retrospective cohort study to examine suicidal thoughts and behaviours
after exposure to smoking cessation products.5
 
In the United States, changes to labelling of varenicline have been based on
biological plausibility and voluntary spontaneous reports, which represent only a small
fraction of all adverse drug reactions.6 Between May 2006 and November 2007, 37
suicides and 127 cases of suicidal ideation were reported in people taking varenicline.3
The Food and Drug Administration (FDA) plans to pay “more specific attention” to
psychiatric side effects in clinical trials of smoking cessation agents in the future.2
 
Gunnell and colleagues assessed 80 660 men and women aged 18-95 who were
prescribed a new course of a smoking cessation product between 2006 and 2008. They
found no association between varenicline or bupropion and fatal or non-fatal self
harm.5 Failure to find such evidence or failure to attain statistical significance is not
the same, however, as finding evidence that supports the null hypothesis over
competing hypotheses.7 The authors note multiple sources of potential confounding. In
addition, FDA analyses of varenicline noted adverse effects within the first two weeks of
exposure.3 Patients experiencing severe adverse events may have discontinued the
prescription before it was finished, yet the authors' analyses assume an exposure equal
to the full prescription and attributed the following three months of outcomes to that
exposure.
 
Given the limitations of these data, clinicians should remain cautious when
prescribing varenicline and bupropion for smoking cessation. The box summarises
current understanding on this topic.
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Current knowledge on products used for smoking cessation
 
* Nicotine replacement products may be useful as a “first line” approach for smoking
cessation
 
* Consistent with the varenicline label, patients should strive to quit “cold turkey” on a
specified date to minimise exposure
 
* Before prescribing or refilling a prescription for varenicline or bupropion, a psychiatric
history and suicide risk assessment using the Beck scale for suicide ideation may be
useful. Current morbidity or distress may suggest use of cessation counselling and
postponement of drugs other than nicotine replacement products
 
* Varenicline is labelled for use in conjunction with counselling, which may also provide
an opportunity to screen for suicidal thoughts or behaviours
 
* Psychiatric morbidity that emerges during treatment should be referred to a mental
health provider
 
* Any serious adverse effects should be reported to the Medicines and Healthcare
Products Regulatory Agency in the UK or the FDA in the US
 
Future research should consider the effectiveness of a variety of nicotine
replacement products in combination (for example, nicotine patch and nicotine gum). In
the US, the Department of Veterans Affairs has tackled the paucity of safety information
on the use of varenicline by developing a guidance document to help providers in the
safe and appropriate use of the agent.8 The department is also conducting a
retrospective cohort study of smoking cessation agents and associated mental health
disorders. The diversity of outcome measures across studies will continue to challenge
direct comparisons. Problems with collecting data—for example, under-reporting
secondary to improper coding—are likely to persist.
 
Data limitations about the risk of suicide may contribute to reports of doctors
disregarding these FDA warnings. In a study of black box warnings on suicide for
gabapentin (used for epilepsy, chronic neuropathic pain, herpes zoster, and hot
flushes), almost half of the US neurologists studied reported that the warning would not
affect their practice.9 Most did not routinely assess depression, and neither did they
warn patients about the potential risk of suicidal thoughts or behaviours, even when
they discussed the risk of other adverse events. Yet, the drug safety literature suggests
that patients would prefer therapeutic failure (to keep smoking) rather than risk
therapeutic harm (suicidal ideation, self harm, or suicide).10 The potential adverse
event is severe, irreversible, immediate, and involves a “dread disease,” whereas other
smoking cessation interventions (nicotine replacement, social support, problem solving,
or skills counselling) are effective and carry no known risk of such side effects. Finally,
patients cannot report suicide related adverse events or make a treatment preference if
doctors do not fully inform them about the risks, uncertain though they may be.
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